Skip to main content
. Author manuscript; available in PMC: 2013 Nov 5.
Published in final edited form as: Mol Pharm. 2012 Oct 16;9(11):3218–3227. doi: 10.1021/mp300303k

Figure 6.

Figure 6

(a) Addition of 2 mM trimethoprim to FITC containing CSANs results in a time dependent loss of fluorescence, due to CSAN disassembly. Conversely, addition of DHFR to bisMTX-FITC results in a concentration dependent increase in FITC fluorescence (data not shown) (b) Treatment of HPB-MLT cells with 2 mM trimethoprim results in loss of green punctates showing intracellular disassembly of CSANs for either 13DHFR2antiCD3 and bisMTX-FITC (c) or 1DHFR2antiCD3 and bisMTX-FITC (e) while DMSO treated cells show no loss of fluorescence (b and d, respectively).